2021年美国风湿病学会/血管炎基金会川崎病管理指南
该指南针对风湿科医生常遇到的川崎病(KD)临床问题,采用PICO格式提出16个临床问题并系统检索文献,用GRADE方法评估证据并形成推荐,需至少70%投票委员共识。共给出1条良好实践声明、11条推荐和1条未分级立场声明,聚焦难治性、重症或复杂KD及疑似KD的管理。
要点
- 所有KD患者均应接受静脉注射免疫球蛋白(IVIG)作为初始治疗。
- 对不完全性KD应 Prompt 治疗、使用阿司匹林,并在不明原因巨噬细胞活化综合征或休克时行超声心动图检查。
- 对具有IVIG抵抗和/或冠状动脉瘤高危特征的患者,条件推荐IVIG联合其他辅助药物。
核心结论
- 该指南为疑似或确诊KD患者的诊断策略、药物使用和超声心动图应用提供指导。
研究设计与样本
- 由美国风湿病学会/血管炎基金会制定,采用PICO格式提出16个临床问题,系统文献检索,GRADE方法评估证据并形成推荐,每条推荐需至少70%投票委员共识。
主要发现
- 共形成1条良好实践声明、11条推荐和1条未分级立场声明,聚焦风湿科医生可能被咨询的难治性、重症或复杂KD及疑似KD场景。
- 在11条推荐中,7条为强推荐,4条为条件推荐。
关键数值与推荐
- 良好实践声明:所有KD患者均应接受IVIG初始治疗。
- 强推荐包括:对不完全性KD进行及时治疗、使用阿司匹林、在不明原因巨噬细胞活化综合征或休克时行超声心动图检查。
- 条件推荐包括:对具有IVIG抵抗和/或冠状动脉瘤高危特征的KD患者,使用IVIG联合其他辅助药物。
临床怎么用
- 这些推荐支持在疾病发作时及时使用已确立的疗法以尽量减少患者风险,并识别可能需要辅助治疗的情况。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide evidence-based recommendations and expert guidance for the management of Kawasaki disease (KD), focusing on clinical scenarios more commonly addressed by rheumatologists. METHODS: Sixteen clinical questions regarding diagnostic testing, treatment, and management of KD were developed in the Patient/Population, Intervention, Comparison, and Outcomes (PICO) question format. Systematic literature reviews were conducted for each PICO question. We used the Grading of Recommendations, Assessment, Development and Evaluation method to assess the quality of evidence and formulate recommendations. Each recommendation required consensus from at least 70% of the Voting Panel. RESULTS: We present 1 good practice statement, 11 recommendations, and 1 ungraded position statement to guide the management of KD and clinical scenarios of suspected KD. These recommendations for KD are focused on situations in which input from rheumatologists may be requested by other managing specialists, such as in cases of treatment-refractory, severe, or complicated KD. The good practice statement affirms that all patients with KD should receive initial treatment with intravenous immunoglobulin (IVIG). In addition, we developed 7 strong and 4 conditional recommendations for the management of KD or suspected KD. Strong recommendations include prompt treatment of incomplete KD, treatment with aspirin, and obtaining an echocardiogram in the setting of unexplained macrophage activation syndrome or shock. Conditional recommendations include use of IVIG with other adjuvant agents for patients with KD and high-risk features of IVIG resistance and/or coronary artery aneurysms. These recommendations endorse minimizing risk to the patient by using established therapy promptly at disease onset and identifying situations in which adjunctive therapy may be warranted. CONCLUSION: These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD.
引用
- Gorelik M, Chung SA, Ardalan K, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Care Res (Hoboken). 2022. PMID: 35257507. doi:10.1002/acr.24838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。